Single-agent oxaliplatin in pretreated advanced breast cancer patients: A phase II study

C. Garufi, C. Nisticò, S. Brienza, A. Vaccaro, A. D'Ottavio, A. R. Zappalà, A. M. Aschelter, E. Terzoli

Research output: Contribution to journalArticle

Abstract

Purpose: Oxaliplatin (L-OHP), a new platinum analogue, is an active drug in colorectal and ovarian cancer. In this phase II study we explored tolerability and activity of oxaliplatin as a single agent in metastatic breast carcinoma patients. Patients and methods: Fourteen anthracycline pretreated advanced breast cancer patients were enrolled. Oxaliplatin was given at 130 mg/m2 on day 1 and repeated every three weeks. Analysis of toxicity, response rate and survival was performed. Results: The median number of courses per patient was four (range 2-6). The median administered dose-intensity was 43.3 mg/m2/week (range 32.5-43.3) which represents 100% of projected dose-intensity. No severe toxicity was encountered. Three patients developed acute transient laryngeal symptoms. Three patients displayed a partial response (21%), (95% confidence interval (CI): 0%-43%), two stable disease (14%) and nine progressed (64%). Response lasted five, four and five months respectively. Median survival was 12 months. Conclusions: In this limited experience, oxaliplatin appeared to be well tolerated and moderately active in advanced anthracycline-pretreated breast cancer patients. Combination chemotherapy with other active drugs such as 5-fluororacil (5-FU), anthracyclines and taxanes should represent the next step of development of this new drug.

Original languageEnglish
Pages (from-to)179-182
Number of pages4
JournalAnnals of Oncology
Volume12
Issue number2
DOIs
Publication statusPublished - 2001

Fingerprint

oxaliplatin
Breast Neoplasms
Anthracyclines
Pharmaceutical Preparations
Taxoids
Combination Drug Therapy
Platinum
Ovarian Neoplasms
Colorectal Neoplasms

Keywords

  • Breast cancer
  • Oxaliplatin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Garufi, C., Nisticò, C., Brienza, S., Vaccaro, A., D'Ottavio, A., Zappalà, A. R., ... Terzoli, E. (2001). Single-agent oxaliplatin in pretreated advanced breast cancer patients: A phase II study. Annals of Oncology, 12(2), 179-182. https://doi.org/10.1023/A:1008386419047

Single-agent oxaliplatin in pretreated advanced breast cancer patients : A phase II study. / Garufi, C.; Nisticò, C.; Brienza, S.; Vaccaro, A.; D'Ottavio, A.; Zappalà, A. R.; Aschelter, A. M.; Terzoli, E.

In: Annals of Oncology, Vol. 12, No. 2, 2001, p. 179-182.

Research output: Contribution to journalArticle

Garufi, C, Nisticò, C, Brienza, S, Vaccaro, A, D'Ottavio, A, Zappalà, AR, Aschelter, AM & Terzoli, E 2001, 'Single-agent oxaliplatin in pretreated advanced breast cancer patients: A phase II study', Annals of Oncology, vol. 12, no. 2, pp. 179-182. https://doi.org/10.1023/A:1008386419047
Garufi C, Nisticò C, Brienza S, Vaccaro A, D'Ottavio A, Zappalà AR et al. Single-agent oxaliplatin in pretreated advanced breast cancer patients: A phase II study. Annals of Oncology. 2001;12(2):179-182. https://doi.org/10.1023/A:1008386419047
Garufi, C. ; Nisticò, C. ; Brienza, S. ; Vaccaro, A. ; D'Ottavio, A. ; Zappalà, A. R. ; Aschelter, A. M. ; Terzoli, E. / Single-agent oxaliplatin in pretreated advanced breast cancer patients : A phase II study. In: Annals of Oncology. 2001 ; Vol. 12, No. 2. pp. 179-182.
@article{dd97e0203c4040b8b91a7d6516888773,
title = "Single-agent oxaliplatin in pretreated advanced breast cancer patients: A phase II study",
abstract = "Purpose: Oxaliplatin (L-OHP), a new platinum analogue, is an active drug in colorectal and ovarian cancer. In this phase II study we explored tolerability and activity of oxaliplatin as a single agent in metastatic breast carcinoma patients. Patients and methods: Fourteen anthracycline pretreated advanced breast cancer patients were enrolled. Oxaliplatin was given at 130 mg/m2 on day 1 and repeated every three weeks. Analysis of toxicity, response rate and survival was performed. Results: The median number of courses per patient was four (range 2-6). The median administered dose-intensity was 43.3 mg/m2/week (range 32.5-43.3) which represents 100{\%} of projected dose-intensity. No severe toxicity was encountered. Three patients developed acute transient laryngeal symptoms. Three patients displayed a partial response (21{\%}), (95{\%} confidence interval (CI): 0{\%}-43{\%}), two stable disease (14{\%}) and nine progressed (64{\%}). Response lasted five, four and five months respectively. Median survival was 12 months. Conclusions: In this limited experience, oxaliplatin appeared to be well tolerated and moderately active in advanced anthracycline-pretreated breast cancer patients. Combination chemotherapy with other active drugs such as 5-fluororacil (5-FU), anthracyclines and taxanes should represent the next step of development of this new drug.",
keywords = "Breast cancer, Oxaliplatin",
author = "C. Garufi and C. Nistic{\`o} and S. Brienza and A. Vaccaro and A. D'Ottavio and Zappal{\`a}, {A. R.} and Aschelter, {A. M.} and E. Terzoli",
year = "2001",
doi = "10.1023/A:1008386419047",
language = "English",
volume = "12",
pages = "179--182",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "2",

}

TY - JOUR

T1 - Single-agent oxaliplatin in pretreated advanced breast cancer patients

T2 - A phase II study

AU - Garufi, C.

AU - Nisticò, C.

AU - Brienza, S.

AU - Vaccaro, A.

AU - D'Ottavio, A.

AU - Zappalà, A. R.

AU - Aschelter, A. M.

AU - Terzoli, E.

PY - 2001

Y1 - 2001

N2 - Purpose: Oxaliplatin (L-OHP), a new platinum analogue, is an active drug in colorectal and ovarian cancer. In this phase II study we explored tolerability and activity of oxaliplatin as a single agent in metastatic breast carcinoma patients. Patients and methods: Fourteen anthracycline pretreated advanced breast cancer patients were enrolled. Oxaliplatin was given at 130 mg/m2 on day 1 and repeated every three weeks. Analysis of toxicity, response rate and survival was performed. Results: The median number of courses per patient was four (range 2-6). The median administered dose-intensity was 43.3 mg/m2/week (range 32.5-43.3) which represents 100% of projected dose-intensity. No severe toxicity was encountered. Three patients developed acute transient laryngeal symptoms. Three patients displayed a partial response (21%), (95% confidence interval (CI): 0%-43%), two stable disease (14%) and nine progressed (64%). Response lasted five, four and five months respectively. Median survival was 12 months. Conclusions: In this limited experience, oxaliplatin appeared to be well tolerated and moderately active in advanced anthracycline-pretreated breast cancer patients. Combination chemotherapy with other active drugs such as 5-fluororacil (5-FU), anthracyclines and taxanes should represent the next step of development of this new drug.

AB - Purpose: Oxaliplatin (L-OHP), a new platinum analogue, is an active drug in colorectal and ovarian cancer. In this phase II study we explored tolerability and activity of oxaliplatin as a single agent in metastatic breast carcinoma patients. Patients and methods: Fourteen anthracycline pretreated advanced breast cancer patients were enrolled. Oxaliplatin was given at 130 mg/m2 on day 1 and repeated every three weeks. Analysis of toxicity, response rate and survival was performed. Results: The median number of courses per patient was four (range 2-6). The median administered dose-intensity was 43.3 mg/m2/week (range 32.5-43.3) which represents 100% of projected dose-intensity. No severe toxicity was encountered. Three patients developed acute transient laryngeal symptoms. Three patients displayed a partial response (21%), (95% confidence interval (CI): 0%-43%), two stable disease (14%) and nine progressed (64%). Response lasted five, four and five months respectively. Median survival was 12 months. Conclusions: In this limited experience, oxaliplatin appeared to be well tolerated and moderately active in advanced anthracycline-pretreated breast cancer patients. Combination chemotherapy with other active drugs such as 5-fluororacil (5-FU), anthracyclines and taxanes should represent the next step of development of this new drug.

KW - Breast cancer

KW - Oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=0035104654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035104654&partnerID=8YFLogxK

U2 - 10.1023/A:1008386419047

DO - 10.1023/A:1008386419047

M3 - Article

C2 - 11300320

AN - SCOPUS:0035104654

VL - 12

SP - 179

EP - 182

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 2

ER -